Ignite Creation Date:
2024-05-05 @ 10:39 PM
Last Modification Date:
2024-10-26 @ 10:21 AM
Study NCT ID:
NCT01151423
Status:
COMPLETED
Last Update Posted:
2023-04-04
First Post:
2010-06-25
Brief Title:
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor vWF Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura aTTP
Sponsor:
Ablynx a Sanofi company
Organization:
Sanofi
Study Overview
Official Title:
A Phase II Single-blind Randomized Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura
Status:
COMPLETED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TITAN
Brief Summary:
This study was a Phase II single-blind randomized placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP
Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange PE
Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange PE
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-019375-30 | EUDRACT_NUMBER | None | None |